Yannis Morel

Yannis Morel, listed as senior executive, appears in our data through filings on Innate Pharma shares, published by AMF. Between 27 January 2022 and 31 December 2025, the trades on record add up to 6 filings.

Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

The record was last updated on 6 January 2026 with a share grant in Innate Pharma. The median gap between a trade and its publication by AMF is 13 days. For comparison, MAR article 19 gives managers three business days to notify a trade. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.